Lacidipine

Lacidipine
Clinical data
Trade names	Lacipil, Motens
AHFS/Drugs.com	International Drug Names
Routes of; administration	Oral
ATC code	C08CA09 (WHO) ;
Legal status
Legal status	In general: ℞ (Prescription only);
Pharmacokinetic data
Bioavailability	~10%
Protein binding	>95%
Metabolism	Hepatic
Onset of action	30–50 min
Elimination half-life	13–19 hours
Excretion	Feces (~70%)
Identifiers
	IUPAC name Diethyl 4-{o-[(E)-2-tert-butoxycarbonylethenyl]phenyl}-2,6-dimethyl-1,4-dihydropyridine-3,5-dicarboxylate;
CAS Number	103890-78-4;
PubChem CID	5311217;
ChemSpider	4470736;
UNII	260080034N;
KEGG	D04657 ;
CompTox Dashboard (EPA)	DTXSID1046429 ;
ECHA InfoCard	100.166.373
Chemical and physical data
Formula	C26H33NO6
Molar mass	455.551 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES CCOC(=O)C1=C(NC(=C(C1C2=CC=CC=C2/C=C/C(=O)OC(C)(C)C)C(=O)OCC)C)C;
	InChI InChI=1S/C26H33NO6/c1-8-31-24(29)21-16(3)27-17(4)22(25(30)32-9-2)23(21)19-13-11-10-12-18(19)14-15-20(28)33-26(5,6)7/h10-15,23,27H,8-9H2,1-7H3/b15-14+; Key:GKQPCPXONLDCMU-CCEZHUSRSA-N;
	(verify)

Lacidipine (tradenames Lacipil or Motens) is a calcium channel blocker. It is available as tablets containing 2 or 4 mg.

It was patented in 1984 and approved for medical use in 1991.^[1]

References

^ Fischer J, Ganellin CR (2006). Analogue-based Drug Discovery. John Wiley & Sons. p. 466. ISBN 9783527607495.

This drug article relating to the cardiovascular system is a stub. You can help Wikipedia by expanding it.